Compound guide · The GH axis
CJC-1295: what it is, its legal status and the evidence
A long-acting GHRH analog, sold with and without the DAC modification.
What the evidence shows
GH/IGF-1 elevation is shown in humans; body-composition benefit in healthy people is not.
Graded in CJC-1295 With DAC vs No DAC (Mod GRF 1-29): The Real Difference for “Body composition improvement (healthy people)”: None shown.
Read the full review: CJC-1295 With DAC vs No DAC (Mod GRF 1-29): The Real Difference
Legal and FDA status
No lawful compounding route, and no pending route either: the nomination that could have created one was pulled. CJC-1295 was not on the July 2026 agenda and is not scheduled for the next meeting, so nothing about its status is moving. FDA has recorded serious adverse events associated with it, including increased heart rate and systemic vasodilatory reaction.
Anti-doping status
Sermorelin, CJC-1295 (with or without DAC), and tesamorelin are synthetic GHRH analogs — they stimulate growth-hormone release and are prohibited at all times under S2. Detection methods for GHRH analogs in urine exist and are advancing. No 2026 change.
Read next: every CJC-1295 guide
What the evidence says
Dosage and how it's taken
How it compares
Is there a legal way to get it?
Not lawful to compound, so we list no sellers of CJC-1295. A prescription option we compare instead:
Calculators
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.